Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A second factor XA inhibitor (novel oral anticoagulant, NOAC), after rivaroxaban, has been approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Apixaban is marketed by Bristol-Myers Squibb and Pfizer as Eliquis.

Pharmacology Update: Apixaban Tablets (Eliquis®)